While this observation is suggestive of increased patient satisfaction with V-Go over other insulin delivery devices, this interpretation is moderated by the observed baseline imbalance in TRIM-Diabetes Device Scores between treatment groups. The gene discussed is INS; the disease is diabetes mellitus.